The RESTORE Registry will assess outcomes of patients with a diagnosis of 5q SMA with biallelic deletion of SMN1, with the primary objective of assessing contemporary SMA treatments, including effectiveness, short- and long-term safety, and overall patient survival. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.